烟台东诚药业集团股份有限公司关于分拆所属 子公司烟台蓝纳成生物技术股份有限公司至香港联合交易所有限公司主板上市的进展公告

Group 1 - The core point of the announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd. plans to spin off its subsidiary Yantai Lanacheng Biotechnology Co., Ltd. for a listing on the main board of the Hong Kong Stock Exchange [1][2] - The company held board meetings and a shareholders' meeting on August 28 and September 15, 2025, respectively, to approve the spin-off plan and related proposals [1] - On September 29, 2025, Lanacheng submitted its application for an initial public offering and listing on the Hong Kong Stock Exchange, with the application materials prepared according to the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [2]